0000000000654362

AUTHOR

Emilia Scalzulli

showing 2 related works from this author

Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs.

2020

OncologyAdultMalemedicine.medical_specialtyAdolescentMyelogenouschemistry.chemical_compoundInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositiveMedicineHumansChildProtein Kinase Inhibitorsbusiness.industryPonatinibLow doseFollow up studiesImidazolesMyeloid leukemiaInfantHematologymedicine.diseasePyridazinesLeukemiachemistryChild PreschoolFemalebusinessFollow-Up StudiesAmerican journal of hematology
researchProduct

A multicenter real‐life study on anticoagulant treatment with direct oral anticoagulants in patients with P h‐negative myeloproliferative neoplasms

2020

NA

medicine.medical_specialtyDOACbusiness.industrymyeloproliferative neoplasmvenous thromboembolismMEDLINEdirect oral anticoagulantAtrial fibrillationHematologymedicine.diseasePhiladelphia chromosomeClinical trialText miningAnticoagulant therapyInternal medicineMedicineLife studybusinessMyeloproliferative neoplasmatrial fibrillation.American Journal of Hematology
researchProduct